Skip to main content

3 Result(s)

within Will Dunlop Remove this filter

and

  1. Article

    Open Access

    Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective

    In the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based conc...

    Will Dunlop, Marjolijn van Keep, Peter Elroy… in PharmacoEconomics - Open (2022)

    Download PDF (932 KB) View Article

  2. Article

    Open Access

    Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine

    Opioid treatment for chronic pain is a known risk factor for falls and/or fractures in elderly patients. The latter cause a significant cost to the National Health Service and the Personal Social Services in t...

    Alexander Hirst, Chris Knight, Matt Hirst… in The European Journal of Health Economics (2016)

    Download PDF (732 KB) View Article

  3. Article

    Open Access

    Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone

    In patients managed with opioids for chronic pain, opioid-induced bowel dysfunction—specifically, opioid-induced constipation (OIC)—is a common side effect, which has a significant impact on quality of life (Q...

    Bart Morlion, Katri Elina Clemens, Will Dunlop in Clinical Drug Investigation (2015)

    Download PDF (385 KB) View Article